Is ABUS A Good Stock To Buy Now?
With the third-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the fourth...
Arbutus Biopharma Corp (ABUS)
Get Email AlertsSector: Pharmaceutical Preparations
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Think Investments Shashin Shah | 2,000,000 | $7,100 | 1.08% | |
| 2. | Hudson Bay Capital Management Sander Gerber | 725,000 | $2,574 | +3% | 0.02% |
| 3. | Renaissance Technologies Jim Simons | 437,963 | $1,555 | 0% | |
| 4. | 251,400 | $892 | +353% | 0% | |
| 5. | Millennium Management Israel Englander | 180,962 | $642 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.95 | 1,000 | Director | 1,000 | 2015-08-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.00 | 20,000 | Officer | 1,307,457 | 2021-02-09 | Filing | |
| $5.00 | 10,000 | Officer | 1,327,457 | 2020-12-14 | Filing | |
| $5.00 | 30,000 | Officer | 1,337,457 | 2020-12-14 | Filing | |
| $5.01 | 20,000 | Officer | 1,367,457 | 2020-07-23 | Filing | |
| $9.51 | 4,250 | Officer | 167,162 | 2018-08-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 5,978,355 | $21,223 | 0.35% | |
| 2. | 2,747,759 | $9,755 | 0% | |
| 3. | 1,821,107 | $6,465 | 0% | |
| 4. | 1,422,264 | $5,049 | 0% | |
| 5. | 1,371,089 | $4,868 | 0.01% |
News See All
Is Arbutus Biopharma Corp (ABUS) A Good Stock To Buy?
In this article we will take a look at whether hedge funds think Arbutus Biopharma Corp (NASDAQ:ABUS) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving...
Arbutus Biopharma Corp (ABUS): Hedge Funds In Wait-and-See Mode
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter of 2018. Trends reversed 180 degrees in 2019 amid Powell's pivot and optimistic...
Here’s What Hedge Funds Think About Arbutus Biopharma Corp (ABUS)
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities...
Do Hedge Funds Love Arbutus Biopharma Corp (ABUS)?
"Value has performed relatively poorly since the 2017 shift, but we believe challenges to the S&P 500’s dominance are mounting and resulting active opportunities away from the index are growing....
13D Filing: QVT Financial and Arbutus Biopharma Corp (ABUS)
previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-l(e), 240.13d-l(f) or 240.13d-1(g),...
13D Filing: Viking Global and Arbutus Biopharma Corp (ABUS)
By: Rose S. Shabet - individually and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES LP, VIKING GLOBAL EQUITIES II LP and VGE III PORTFOLIO...
QVT Financial’s Investments, Performance, Letters
Daniel Gold, who holds a Bachelor of Arts degree in Physics from Harvard College, founded QVT Financial in 2004 after having worked for several years as a star trader at Deutsche Bank. QVT started inside...
13D Filing: Viking Global and Arbutus Biopharma Corp (ABUS)
The calculation assumes that there are a total of 55,024,557 Common Shares outstanding as of April 30, 2017, as reported by the Issuer on its Quarterly Report on Form 10-Q for the period ended March 31...
Billionaire Hedge Funds
